$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022012662 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$93.69M	$98.82M	$79.44M
YoY Change	17.94%	15.26%	-14.81%
Cost Of Revenue	$1.250M	$1.354M	$1.268M
YoY Change	-1.42%	8.32%	-32.48%
Gross Profit	$92.44M	$97.47M	$78.17M
YoY Change	18.25%	15.37%	-14.45%
Gross Profit Margin	98.67%	98.63%	98.4%
Selling, General & Admin	$37.55M	$32.28M	$29.51M
YoY Change	27.25%	25.62%	7.17%
% of Gross Profit	40.62%	33.12%	37.75%
Research & Development	$28.12M	$28.52M	$29.02M
YoY Change	-3.11%	0.85%	11.1%
% of Gross Profit	30.42%	29.26%	37.13%
Depreciation & Amortization	$288.0K	$289.0K	$254.0K
YoY Change	13.39%	189.0%	6.72%
% of Gross Profit	0.31%	0.3%	0.32%
Operating Expenses	$65.67M	$60.80M	$58.53M
YoY Change	12.2%	12.64%	9.08%
Operating Profit	$26.77M	$36.66M	$19.64M
YoY Change	36.31%	20.21%	-47.93%
Interest Expense	$80.00K	$72.00K	$280.0K
YoY Change	-71.43%	-76.0%	-80.95%
% of Operating Profit	0.3%	0.2%	1.43%
Other Income/Expense, Net	$80.00K		$275.0K
YoY Change	-70.91%		-81.31%
Pretax Income	$26.85M	$36.74M	$19.91M
YoY Change	34.83%	19.23%	-49.18%
Income Tax	$4.100M	$4.683M	-$3.600M
% Of Pretax Income	15.27%	12.75%	-18.08%
Net Earnings	$22.80M	$32.05M	$23.47M
YoY Change	-2.85%	23.31%	-21.95%
Net Earnings / Revenue	24.33%	32.44%	29.54%
Basic Earnings Per Share	$0.22		$0.20
Diluted Earnings Per Share	$0.20	$262.0K	$0.18
COMMON SHARES
Basic Shares Outstanding	106.0M shares	115.5M shares	116.8M shares
Diluted Shares Outstanding	115.0M shares		129.7M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$345.5M	$223.5M	$373.0M
YoY Change	-7.37%	-49.28%	21.38%
Cash & Equivalents	$61.86M	$77.62M	$52.38M
Short-Term Investments	$283.7M	$145.9M	$320.6M
Other Short-Term Assets	$10.44M	$10.32M	$9.500M
YoY Change	9.85%	53.96%	66.67%
Inventory	$5.079M	$4.988M	$4.948M
Prepaid Expenses
Receivables	$27.18M	$27.63M	$22.20M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$388.2M	$266.5M	$409.6M
YoY Change	-5.23%	-44.31%	18.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$726.0K	$1.002M	$1.481M
YoY Change	-50.98%	-40.18%	68.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$22.57M	$112.3M	$81.80M
YoY Change	-72.41%	210.16%	96.16%
Other Assets	$2.984M	$3.083M	$5.030M
YoY Change	-40.68%	-38.34%	46.18%
Total Long-Term Assets	$79.90M	$157.3M	$142.8M
YoY Change	-44.04%	68.72%	41.76%
TOTAL ASSETS
Total Short-Term Assets	$388.2M	$266.5M	$409.6M
Total Long-Term Assets	$79.90M	$157.3M	$142.8M
Total Assets	$468.1M	$423.8M	$552.4M
YoY Change	-15.26%	-25.88%	24.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.269M	$6.908M	$6.969M
YoY Change	33.0%	-34.55%	40.05%
Accrued Expenses	$32.66M	$27.67M	$18.00M
YoY Change	81.45%	30.58%	-8.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$57.24M	$47.54M	$40.60M
YoY Change	40.99%	0.1%	19.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.068M	$409.0K	$1.000M
YoY Change	206.8%	-54.56%	-47.37%
Total Long-Term Liabilities	$3.068M	$409.0K	$1.000M
YoY Change	206.8%	-54.56%	-47.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.24M	$47.54M	$40.60M
Total Long-Term Liabilities	$3.068M	$409.0K	$1.000M
Total Liabilities	$60.31M	$47.95M	$41.60M
YoY Change	44.99%	-0.92%	15.53%
SHAREHOLDERS EQUITY
Retained Earnings	$217.8M	$195.0M	$105.9M
YoY Change	105.59%	136.45%	1527.05%
Common Stock	$608.8M	$591.5M	$536.5M
YoY Change	13.49%	14.57%	15.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$407.8M	$375.8M	$510.8M
YoY Change
Total Liabilities & Shareholders Equity	$468.1M	$423.8M	$552.4M
YoY Change	-15.26%	-25.88%	24.0%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	$22.80M	$32.05M	$23.47M
YoY Change	-2.85%	23.31%	-21.95%
Depreciation, Depletion And Amortization	$288.0K	$289.0K	$254.0K
YoY Change	13.39%	189.0%	6.72%
Cash From Operating Activities	$35.25M	$49.43M	$25.42M
YoY Change	38.65%	40.82%	-23.59%
INVESTING ACTIVITIES
Capital Expenditures	$12.00K	-$65.00K	$126.0K
YoY Change	-90.48%	-83.75%	200.0%
Acquisitions
YoY Change
Other Investing Activities	-$50.48M	$140.5M	-$3.200M
YoY Change	1477.63%	1101.16%	-116.16%
Cash From Investing Activities	-$50.50M	$140.5M	-$3.284M
YoY Change	1437.64%	1154.21%	-116.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$33.54M
YoY Change	-100.0%		12096.73%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$506.0K	-207.0M	-$45.95M
YoY Change	-98.9%	29467.0%	-22513.17%
NET CHANGE
Cash From Operating Activities	$35.25M	49.43M	$25.42M
Cash From Investing Activities	-$50.50M	140.5M	-$3.284M
Cash From Financing Activities	-$506.0K	-207.0M	-$45.95M
Net Change In Cash	-$15.76M	-17.07M	-$23.81M
YoY Change	-33.83%	-137.44%	-144.75%
FREE CASH FLOW
Cash From Operating Activities	$35.25M	$49.43M	$25.42M
Capital Expenditures	$12.00K	-$65.00K	$126.0K
Free Cash Flow	$35.24M	$49.49M	$25.30M
YoY Change	39.29%	39.41%	-23.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001088856
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106250716	shares
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	000-50679
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CORCEPT THERAPEUTICS INC
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0487658
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	149 Commonwealth Drive
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
CY2022Q1	dei	City Area Code CityAreaCode	650
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	327-3270
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022Q1	dei	Trading Symbol TradingSymbol	CORT
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	us-gaap	Inventory Net InventoryNet	4988000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61862000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77617000	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	283665000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	145918000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27178000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27625000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	5079000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10436000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10315000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	388220000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	266463000	USD
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	13098000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12962000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2816000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	514000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	726000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1002000	USD
CY2022Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	22566000	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	112277000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2984000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3083000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	37713000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27455000	USD
CY2022Q1	us-gaap	Assets Assets	468123000	USD
CY2021Q4	us-gaap	Assets Assets	423756000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9269000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6908000	USD
CY2022Q1	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13051000	USD
CY2021Q4	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	12442000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32660000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27665000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	409000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	60312000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2264000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	526000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	57244000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47541000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	552000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	2516000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	47950000	USD
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	128000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	127000	USD
CY2022Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	417448000	USD
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	410411000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	608717000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	591349000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1351000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-227000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	217765000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	468123000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	423756000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	194968000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	407811000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	375806000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	93688000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79437000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1250000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1268000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28120000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29022000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	275000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37549000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29509000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	66919000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	59799000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	26769000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	19638000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	80000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	26849000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19913000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4052000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3552000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	22797000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	323000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	61000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1019000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10101000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-192000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-105000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	26000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21673000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	23299000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106012000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116818000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115037000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129668000	shares
CY2022Q1	us-gaap	Profit Loss ProfitLoss	22797000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	23465000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10761000	USD
CY2022Q1	cort	Accretion Expense Income AccretionExpenseIncome	1106000	USD
CY2021Q1	cort	Accretion Expense Income AccretionExpenseIncome	1194000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	288000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	254000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9935000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5360000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	514000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	489000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-447000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3998000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	163000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-866000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2850000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2256000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3493000	USD
CY2022Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	609000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-484000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	25422000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	35247000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	126000	USD
CY2021Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	-138000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4995000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3217000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	2107000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	597000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-526000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	42127000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	124230000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	92611000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	127388000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50496000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3284000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1382000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4038000	USD
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	33541000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1888000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16444000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-506000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-45947000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15755000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23809000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77617000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76190000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61862000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52381000	USD
CY2022Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	5149000	USD
CY2021Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	6045000	USD
CY2022Q1	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	2816000	USD
CY2021Q1	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	523338000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10083000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	33540000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22520000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10142000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-166000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	510802000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	375806000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6544000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7037000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10825000	USD
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1124000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	22797000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	407811000	USD
CY2022Q1	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
CY2022Q1	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	12637000	USD
CY2021Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	11450000	USD
CY2022Q1	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	5540000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	5079000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4988000	USD
CY2021Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	6500000	USD
CY2022Q1	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	18177000	USD
CY2021Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	17950000	USD
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	13098000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12962000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3939000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3927000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3213000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2925000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	726000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1002000	USD
CY2022Q1	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	12377000	USD
CY2021Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11174000	USD
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	11523000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	513000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4968000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13339000	USD
CY2022Q1	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	1802000	USD
CY2021Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	842000	USD
CY2022Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	861000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1351000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	652000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	150000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	477000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	296000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32660000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27665000	USD
CY2022Q1	cort	Deposits For Clinical Trials DepositsForClinicalTrials	2800000	USD
CY2021Q4	cort	Deposits For Clinical Trials DepositsForClinicalTrials	2900000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	330497000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	303283000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1400000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	400000	USD
CY2022Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	1000000	USD
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1400000	USD
CY2022Q1	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P2Y
CY2022Q1	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P7M
CY2022Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2022Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2800000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2800000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	530000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	514000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2816000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15M
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.048
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1735000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1157000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2892000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2816000	USD
CY2022Q1	cort	Number Of Stock Option Plans NumberOfStockOptionPlans	1	stockOptionPlan
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	600000	shares
CY2022Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	300000	shares
CY2021Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	800000	shares
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1900000	USD
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1800000	shares
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16400000	USD
CY2022Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	21600000	shares
CY2021Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	21300000	shares
CY2022Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	64000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	41000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10825000	USD
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10142000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	22797000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	23465000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106012000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116818000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9025000	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	12850000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115037000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129668000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26800000	shares
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4100000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	400000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7700000	USD
CY2022Q1	cort	Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance	1900000	USD
CY2022Q1	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	11500000	USD
CY2021Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	500000	USD

Files In Submission

Name	View Source	Status
0001628280-22-012662-index-headers.html	Edgar Link	pending
0001628280-22-012662-index.html	Edgar Link	pending
0001628280-22-012662.txt	Edgar Link	pending
0001628280-22-012662-xbrl.zip	Edgar Link	pending
cort-20220331.htm	Edgar Link	pending
cort-20220331.xsd	Edgar Link	pending
cort-20220331_cal.xml	Edgar Link	unprocessable
cort-20220331_def.xml	Edgar Link	unprocessable
cort-20220331_htm.xml	Edgar Link	completed
cort-20220331_lab.xml	Edgar Link	unprocessable
cort-20220331_pre.xml	Edgar Link	unprocessable
cort33122ex101seventhamend.htm	Edgar Link	pending
cort33122ex311.htm	Edgar Link	pending
cort33122ex312.htm	Edgar Link	pending
cort33122ex321.htm	Edgar Link	pending
cort33122ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2022 Q1 Form 10-Q Financial Statement

#000162828022012662 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2022 Q1 Form 10-Q Financial Statement

#000162828022012662 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort